QUTENZA

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Painful Diabetic Peripheral Neuropathy (PDPN)

Conditions

Painful Diabetic Peripheral Neuropathy (PDPN)

Trial Timeline

Nov 1, 2011 → Feb 1, 2014

NCT ID

NCT01478607

About QUTENZA

QUTENZA is a phase 3 stage product being developed by Astellas Pharma for Painful Diabetic Peripheral Neuropathy (PDPN). The current trial status is completed. This product is registered under clinical trial identifier NCT01478607. Target conditions include Painful Diabetic Peripheral Neuropathy (PDPN).

What happened to similar drugs?

7 of 20 similar drugs in Painful Diabetic Peripheral Neuropathy (PDPN) were approved

Approved (7) Terminated (2) Active (11)

✅Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacainePacira BiosciencesApproved

✅Qutenza + PregabalinAstellas PharmaApproved

✅duloxetine hydrochlorideEli LillyApproved

🔄Duloxetine hydrochloride + placeboEli LillyPhase 3

🔄Duloxetine + PlaceboEli LillyPhase 3

✅duloxetine hydrochloride + pregabalin + gabapentinEli LillyApproved

🔄Duloxetine + Pregabalin + PlaceboEli LillyPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02171182	Pre-clinical	Completed	Jan 1, 2014	Aug 1, 2015	Post-operative Peripheral Neuropathic Pain
NCT01478607	Phase 3	Completed	Nov 1, 2011	Feb 1, 2014	Painful Diabetic Peripheral Neuropathy (PDPN)
NCT01252160	Approved	Completed	Oct 28, 2010	Sep 26, 2013	Neuralgia, Postherpetic

Competing Products

20 competing products in Painful Diabetic Peripheral Neuropathy (PDPN)

See all competitors

Product	Company	Stage	Hype Score
Popliteal nerve block including liposomal bupivacaine + Adductor canal nerve block including liposomal bupivacaine + Continuous popliteal nerve block with normal saline + Popliteal nerve block with exclusively unencapsulated bupivacaine + Adductor canal nerve block with exclusively unencapsulated bupivacaine + Continuous popliteal nerve block with unencapsulated bupivacaine	Pacira Biosciences	Approved	44
ASP3662 + pregabalin + ASP3662 placebo + pregabalin placebo	Astellas Pharma	Phase 2	27
Qutenza + Pregabalin	Astellas Pharma	Approved	43
duloxetine hydrochloride	Eli Lilly	Approved	43
Duloxetine hydrochloride + placebo	Eli Lilly	Phase 3	40
Duloxetine + Placebo	Eli Lilly	Phase 3	40
duloxetine hydrochloride + pregabalin + gabapentin	Eli Lilly	Approved	43
Duloxetine + Pregabalin + Placebo	Eli Lilly	Phase 3	40
Placebo + Pregabalin + LY545694 21 mg + LY545694 49 mg + LY545694 105 mg	Eli Lilly	Phase 2	35
GRC 17356 + Matching Placebo	Glenmark Pharmaceuticals	Phase 2	35
GRC 17536 (Medium Dose) + GRC 17536 (Low Dose) + Placebo	Glenmark Pharmaceuticals	Phase 2	27
Tapentadol extended release (ER) + Oxycodone controlled release (CR)	Johnson & Johnson	Phase 3	32
AZD5213 + pregabalin + Placebo + pregabalin capsules	AstraZeneca	Phase 2	35
MEDI7352	AstraZeneca	Phase 2	27
MEDI7352	AstraZeneca	Phase 2	35
MEDI7352 + Placebo	AstraZeneca	Phase 1	29
MK-6096 + Placebo	Merck	Phase 2	35
Comparator: A: Pregabalin + Comparator: B: Duloxetine + Comparator: C: Diphenhydramine hydrochloride	Merck	Phase 2	27
EMA401 + Placebo	Novartis	Phase 2	27
Pregabalin	Pfizer	Phase 3	40